Navigation Links
United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
Date:10/28/2010

l as a lower estimate of business tax credits expected to be generated compared to the same period in 2009. These factors increased the estimated annual effective tax rate for the three months ended September 30, 2010 when compared to the same period in 2009.

Earnings before Non-Cash Charges Earnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (i) interest; (ii) income taxes; (iii) license fees; (iv) depreciation and amortization; (v) impairment charges; and (vi) share-based compensation (stock option and share tracking award expense).

The following table provides a reconciliation of net income to earnings before non-cash charges for each of the quarters ended September 30, 2010 and 2009 (in thousands, except per share data):Three Months Ended
September 30,20102009Net income, as reported$

39,736$

11,937Adjust for non-cash charges:Interest expense4,8093,331Income tax expense (benefit)17,998(2,891)License fees --Depreciation and amortization5,0282,505Impairment charges-399Share-based compensation31,50025,293Earnings before non-cash charges$

99,071$

40,574Earnings before non-cash charges per share(1):Basic$

1.75$

0.76Diluted$

1.65$

0.70(1) Calculated by dividing earnings before non-cash charges by the basic and diluted weighted average number of common shares outstanding, as reported below in our Consolidated Statements of Operations.Conference CallWe will host a half-hour teleconference on Thursday, October 28, 2010 at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using conference code: 14787030.

This teleconference is also be
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Jan. 31, 2012  Argos Therapeutics Inc., today announced ... analysis of AGS-003-006, a Phase 2 study of ... in patients with advanced renal cell carcinoma (RCC). ... anti-tumor memory T cell responses and overall survival. ...
... 2012   Veracyte, Inc ., a molecular diagnostics company ... the appointment of Mark Spring as chief financial officer. ... has joined the Veracyte team," said Bonnie Anderson, Veracyte,s ... a CFO and senior finance leader in both public ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... the following upcoming investment conferences in February. ... present at the Leerink Swann 2012 Global Healthcare Conference ... Life Technologies will also present at the 2012 ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Life Technologies to Present at Upcoming Investment Conferences in February 2
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... has been a well-kept secret of our immune system,s success. The ... Cell Press publication, offer an explanation for how specialized immune cells ... in the process. The focus of the study is a ... a pore in cells targeted for destruction. With that pore in ...
... uncovered a new role for a key cancer protein, a ... of a variety of tumors. Many cancers are driven ... the cells to escape growth controls and proliferate abnormally. In ... Nature , researchers discovered that cyclin D1 also helps ...
... Evidence from benchmark sites across the ... allows for land-use sharing in agriculture, forests and other ... gas emissions and raising food production levels. It provides ... land for forests through agricultural intensification. Agricultural intensification, also ...
Cached Biology News:How killer immune cells avoid killing themselves 2Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3Integrating agriculture and forestry in the landscape is key to REDD 2
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
MMP-1/8 (H-300)...
... contains choice of Printing Surface (3 glass slides coated ... layer, 1 silicon wafer coated with 1000 Angstroms of ... slides) and PDMS Stamps (3 PDMS micropatterned stamps with ... um x 10 mm or 200 um x 10 ...
Biology Products: